ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $18.83 Average PT from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $18.83.

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus restated a “hold” rating and set a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO opened at $15.60 on Wednesday. ALX Oncology has a 1 year low of $3.94 and a 1 year high of $17.42. The firm has a market cap of $780 million, a P/E ratio of -4.16 and a beta of 1.58. The stock has a fifty day moving average price of $13.59 and a two-hundred day moving average price of $11.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Research analysts forecast that ALX Oncology will post -3.33 EPS for the current fiscal year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total transaction of $710,000.00. Following the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at approximately $8,579,711. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Jaume Pons sold 50,000 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at approximately $8,579,711. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jason Lettmann bought 4,400 shares of the stock in a transaction on Thursday, March 14th. The shares were acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the purchase, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ALXO. FMR LLC increased its position in ALX Oncology by 0.3% in the 1st quarter. FMR LLC now owns 6,129,441 shares of the company’s stock worth $27,705,000 after purchasing an additional 16,013 shares during the last quarter. State Street Corp grew its stake in shares of ALX Oncology by 47.9% in the 1st quarter. State Street Corp now owns 2,133,744 shares of the company’s stock valued at $36,060,000 after buying an additional 691,410 shares in the last quarter. BlackRock Inc. increased its holdings in ALX Oncology by 7.2% in the second quarter. BlackRock Inc. now owns 1,788,760 shares of the company’s stock worth $13,434,000 after buying an additional 120,136 shares during the last quarter. Vestal Point Capital LP bought a new position in ALX Oncology during the fourth quarter valued at approximately $24,643,000. Finally, Vanguard Group Inc. lifted its stake in ALX Oncology by 49.0% in the fourth quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock valued at $22,371,000 after acquiring an additional 494,173 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.